Skip to main content

Advertisement

SpringerLink
Log in

Comparison of the detecting capability between 123I-mIBG and post-therapeutic 131I-mIBG scintigraphy for curie scoring in patients with neuroblastoma after chemotherapy

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

To evaluate the detecting capability between planar imaging (PI) and PI combined with single-photon emission computed tomography/computed tomography (PICWS), including 123I- and 131I-labeled metaiodobenzylguanidine (mIBG) and to compare the detecting capability between 123I-mIBG and post-therapeutic 131I-mIBG scintigraphy including PI and PICWS for Curie scoring in patients with neuroblastoma.

Methods

Sixty-two patients with 66 pairs of complete images with neuroblastoma were enrolled in this retrospective study.

Results

Comparing the Curie scoring between 123I-mIBG PI and PICWS and between post-therapeutic 131I-mIBG PI and PICWS, findings were concordantly negative in 28.79% and 18.18% of studies, concordantly positive in 66.67% and 74.24% of studies, and discordant in 4.54% and 7.58% of studies, respectively. PICWS was superior to PI including 123I- and 131I-mIBG in the evaluation of Curie scoring for neuroblastoma patients (both P < 0.001). Comparing the Curie scores between 123I- and post-therapeutic 131I-mIBG PI and between 123I- and post-therapeutic 131I-mIBG PICWS, concordantly negative imaging was visualized in 22.73% and 19.70% of studies, concordantly positive imaging in 66.67% and 69.70% of studies, and discordant imaging in 10.60% and 10.60% of studies, respectively. Post-therapeutic 131I-mIBG was significantly better than that of 123I-mIBG scintigraphy including PI and PICWS in detecting the Curie scoring for neuroblastoma patients (both P < 0.001).

Conclusion

The present study demonstrates that 131I- or 123I-mIBG PICWS are more helpful in the evaluation of Curie scores than that of conventional PI and that post-therapeutic 131I-mIBG is superior to 123I-mIBG scintigraphy for the detecting capability of Curie scoring in patients with neuroblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Matthay KK, Villablanca JG, Seeger RC, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–73.

    Article  CAS  Google Scholar 

  2. Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol. 2009;23:125–43.

    Article  Google Scholar 

  3. Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2011;47:561–71.

    Article  Google Scholar 

  4. Parisi MT, Eslamy H, Park JR, Shulkin BL, Yanik GA. 131I-Metaiodobenzylguanidine theranostics in neuroblastoma: historical perspectives. Practical applications. Semin Nucl Med. 2016;46:184–202.

    Article  Google Scholar 

  5. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PE, Brodeur GM, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27:289–97.

    Article  Google Scholar 

  6. Radovic B, Artiko V, Sobic-Saranovic D, Trajkovic G, Markovic S, Vujic D, et al. Evaluation of the SIOPEN semi-quantitative scoring system in planar simpatico-adrenal MIBG scintigraphy in children with neuroblastoma. Neoplasma. 2015;62:449–55.

    Article  CAS  Google Scholar 

  7. Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol. 1999;6:119–24.

    Article  CAS  Google Scholar 

  8. Koopmans KP, Neels ON, Kema IP, Elsinga PH, Links TP, de Vries EGE, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol. 2009;71:199–213.

    Article  Google Scholar 

  9. Fukuoka M, Taki J, Mochizuki T, Kinuya S. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/paraganglioma and neuroblastoma. Clin Nucl Med. 2011;36:1–7.

    Article  Google Scholar 

  10. Wong KK, Gandhi A, Viglianti BL, Fig LM, Rubello D, Gross MD. Endocrine radionuclide scintigraphy with fusion single photon emission computed tomography/computed tomography. World J Radiol. 2016;8:635–55.

    Article  Google Scholar 

  11. Scherübl H, Raue F, Frank-Raue K. Neuroendocrine tumors : Classification, clinical presentation and imaging. Radiologe. 2019;59:952–60.

    Article  Google Scholar 

  12. Riaz S, Bashir H, Khan SJ, Qazi A. I-131 mIBG scintigraphy curie versus SIOPEN scoring: prognostic value in stage 4 neuroblastoma. Mol Imaging Radionucl Ther. 2018;27:121–5.

    Article  Google Scholar 

  13. Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol. 2013;31:944–51.

    Article  CAS  Google Scholar 

  14. Olivier P, Colarinha P, Fettich J, Fischer S, Frökier J, Giammarile F, et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging. 2003;30:B45-50.

    Article  Google Scholar 

  15. Matthay KK, Edeline V, Lumbroso J, Tanguy ML, Asselain B, Zucker JM, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21:2486–91.

    Article  Google Scholar 

  16. Messina JA, Cheng SC, Franc BL, Charron M, Barry Shulkin B, To B, et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer. 2006;47:865–74.

    Article  Google Scholar 

  17. Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s oncology group. J Nucl Med. 2013;54:541–8.

    Article  CAS  Google Scholar 

  18. Lynn MD, Shapiro B, Sisson JC, Beierwaltes WH, Meyers LJ, Ackerman R, et al. Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology. 1985;155:789–92.

    Article  CAS  Google Scholar 

  19. Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC. Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med. 1986;11:851–4.

    Article  CAS  Google Scholar 

  20. Pfannenberg AC, Eschmann SM, Horger M, Lamberts R, Vonthein R, Claussen CD, et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2003;30:835–43.

    Article  Google Scholar 

  21. Moreira AP, Duarte LH, Vieira F, João F, Lima JP. Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy. Rev Esp Med Nucl. 2005;24:14–8.

    Article  Google Scholar 

  22. Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol. 2008;190:1085–90.

    Article  Google Scholar 

  23. Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med. 2009;50:184–90.

    Article  Google Scholar 

  24. Theerakulpisut D, Raruenrom Y, Wongsurawat N, Somboonporn C. Value of SPECT/CT in diagnostic I-131 MIBG scintigraphy in patients with neuroblastoma. Nucl Med Mol Imaging. 2018;52:350–8.

    Article  Google Scholar 

  25. Černý I, Prášek J, Kašpárková H. Superiority of SPECT/CT over planar 123I-mIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values. Nuklearmedizin. 2016;55:151–7.

    PubMed  Google Scholar 

  26. Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG, et al. Comparison of 123I-metaiodobenzylguanidine (MIBG) and 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2011;56:1041–5.

    Article  Google Scholar 

  27. Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG. Med Pediatr Oncol. 1987;15:170–7.

    Article  CAS  Google Scholar 

  28. Kayano D, Taki J, Fukuoka M, Wakabayashi H, Inaki A, Nakamura A, et al. Low-dose (123)I-metaiodobenzylguanidine diagnostic scan is inferior to (131)I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma. Nucl Med Commun. 2011;32:941–6.

    Article  CAS  Google Scholar 

  29. Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol. 2000;35(2):153–5.

    Article  CAS  Google Scholar 

  30. Bleeker G, Tytgat GA, Adam JA, Caron HN, Kremer LCM, Hooft L, et al. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev. 2015;1:009263.

    Google Scholar 

  31. Kong G, Hofman MS, Murray WK, Wilson S, Wood P, Downie P, et al. Initial experience with gallium-68 DOTA-octreotate PET/CT and Peptide Receptor Radionuclide Therapy For Pediatric Patients With Refractory Metastatic Neuroblastoma. J Pediatr Hematol Oncol. 2016;38(2):87–96.

    Article  CAS  Google Scholar 

  32. Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging. 2012;39:57–71.

    Article  CAS  Google Scholar 

  33. Piccardo A, Puntoni M, Lopci E, Conte M, Foppiani L, Sorrentino S, et al. Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. Eur J Nucl Med Mol Imaging. 2014;41:1046–56.

    Article  Google Scholar 

  34. Reuland P, Geiger L, Thelen MH, Handgretinger R, Haase B, Müller-Schauenburg W, et al. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response. J Pediatr Hematol Oncol. 2001;23:437–42.

    Article  CAS  Google Scholar 

  35. Cistaro A, Quartuccio N, Caobelli F, Piccardo A, Paratore R, Coppolino P, et al. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma. Nucl Med Rev Cent East Eur. 2015;18:102–6.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Zhong-Ling Qiu and Shintaro Saito Joint first authors contributed equally to this work.

Authors and Affiliations

  1. Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Road, Shanghai, 200233, China

    Zhong-Ling Qiu

  2. Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan

    Shintaro Saito, Daiki Kayano, Hiroshi Wakabayashi & Seigo Kinuya

Authors
  1. Zhong-Ling Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shintaro Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daiki Kayano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroshi Wakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seigo Kinuya
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DK and SK designed the present study. ZLQ and SS conducted the statistical analysis. ZLQ and SS collected the clinical data. ZLQ wrote the whole paper. ZLQ, DK, and HW supervised and edited the paper. All authors read and approved the final paper.

Corresponding author

Correspondence to Daiki Kayano.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study protocol was approved by the Ethics Committee of the Kanazawa University Hospital.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qiu, ZL., Saito, S., Kayano, D. et al. Comparison of the detecting capability between 123I-mIBG and post-therapeutic 131I-mIBG scintigraphy for curie scoring in patients with neuroblastoma after chemotherapy. Ann Nucl Med 35, 649–661 (2021). https://doi.org/10.1007/s12149-020-01569-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-020-01569-1

Keywords

Search

Navigation